Cardiomyopathy/Myocarditis
RSSArticles
-
COVID-19 Infection More Likely to Inflame Heart Than Vaccine
Researchers noted patients were much more likely to be afflicted with myocarditis after a SARS-CoV-2 infection than after receiving a vaccine.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.
-
Outcomes of COVID-19-Associated Acute Myocarditis
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.
-
Cardiology Groups Standardize COVID-19 Diagnosis, Treatment Definitions
Guide provides clinicians with uniform information on symptom recognition, risk factors, testing, and more.
-
Mavacamten Capsules (Camzyos)
Mavacamten can be prescribed to adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
-
Outcomes of COVID-19-Associated Acute Myocarditis
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.
-
Investigators Use Personalized Modeling to Diagnose Hypertrophic Cardiomyopathy
Blended techniques could help clinicians draft more effective treatment plans.
-
Significance of Flail Mitral Leaflet and Wall-Impinging Regurgitant Flow
Using cardiac MRI as a gold standard, the presence of a flail mitral leaflet or a wall-impinging mitral regurgitant jet on transthoracic echocardiography were associated with severe mitral regurgitation, but not diagnostic of it.
-
New Treatment for Hypertrophic Obstructive Cardiomyopathy
A study of the echocardiographic characteristics of symptomatic patients with obstructive hypertrophic cardiomyopathy treated with mavacamten showed a persistent 30-week improvement in several key pathophysiologic characteristics.
-
Screen Older Heart Failure Patients for Transthyretin Cardiac Amyloidosis
A screening study of heart failure patients ≥ age 60 years, left ventricular ejection fraction ≥ 40%, and left ventricle wall thickness ≥ 12 mm revealed 6.3% prevalence of transthyretin cardiac amyloidosis, a highly treatable disease.